logoTry Persana

Cellares - Company Overview, Founder, CEO, Funding & Investment Details

Complete information about Cellares including founder details, CEO information, total funding raised, headquarters location, team size, and recent investment rounds.

Cellares company logo

Accelerating Access to Life-Saving Cell Therapies

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) dedicated to cell therapy manufacturing, utilizing advanced technologies to accelerate access to life-saving treatments.

HeadquartersSouth San Francisco, United States
Team size201-500
Founded2019

What is Cellares? - Company Overview & Details

Cellares is Cellares is the first Integrated Development and Manufacturing Organization (IDMO) dedicated to cell therapy manufacturing, utilizing advanced technologies to accelerate access to life-saving treatments. Founded in 2019, the company is headquartered in South San Francisco, United States.

Who Founded Cellares?

Cellares was founded by Fabian Gerlinghaus.

Who are the Key Executives at Cellares? - Leadership Team

Cellares is led by experienced executives in key positions:

Cellares Company Details & Key Information

Where is Cellares located?

Cellares is headquartered in South San Francisco, United States.

How many employees does Cellares have?

Cellares has 201-500 employees.

When was Cellares founded?

Cellares was founded in 2019.

How much funding has Cellares raised?

Cellares has raised $355 Million across 3 funding rounds. The most recent funding was completed on 2023-09-23.

Funding Overview

Cellares raised a total of $355 million in various funding rounds to enhance its automated cell therapy manufacturing technology.

$355 Million
Total Funding Raised
3
Funding Rounds
2023-09-23
Latest Round

Cellares Funding History

Series C
2023-09-23
$255 Million
Series B
2021-05-05
$82 Million
Series A
2019-08-01
$18 Million

Who are the key investors in Cellares?

Cellares is backed by 1 key investors including Koch Disruptive Technologies. These investors focus on Biotechnology, Healthcare sectors.

Cellares Investor Overview

1
Key Investors
2
Focus Areas
1
Notable Investments

Complete List of Cellares Investors

Koch Disruptive Technologies

An investment firm focused on disruptive technologies.

Investment Focus
Biotechnology
Healthcare
Notable Portfolio Companies
Cellares

What sectors do Cellares investors focus on?

The investors backing Cellares primarily focus on Biotechnology, Healthcare sectors.

Biotechnology
Healthcare

Featured Investor: Koch Disruptive Technologies

Koch Disruptive Technologies

An investment firm focused on disruptive technologies.

Notable Investments: Cellares

What are Cellares's future plans?

Cellares Cellares is focused on expanding its manufacturing capabilities and enhancing its technology platform globally.

Cellares Strategic Outlook

Strategic Focus
Defined
2
Key Challenges
2
Growth Opportunities

What challenges does Cellares face?

Cellares has identified 2 key challenges that need to be addressed for continued growth and success.

Key Challenges for Cellares

1

Scaling manufacturing processes

2

Meeting global patient demand

What opportunities does Cellares have?

Cellares has identified 2 key opportunities for growth and market expansion.

Growth Opportunities for Cellares

1

Expanding into new markets

2

Partnerships with major pharmaceutical companies

Cellares Strategic Position Summary

Key Focus Areas

Cellares is addressing 2 strategic challenges to strengthen its market position.

Growth Potential

The company has identified 2 key opportunities for expansion and growth.

What are the latest news about Cellares?

Cellares has 2 recent news updates covering key business developments and market activities.

Cellares News Overview

2
Recent Articles
Active
Media Coverage
2025-05-30
Latest Update

What is Cellares in the news for?

Cellares is currently featured in news for Cellares Corporation partners with Mitsui Fudosan Realty Co. and other significant business developments.

Recent News Articles About Cellares

Article 1
2025-05-30

Cellares Corporation partners with Mitsui Fudosan Realty Co.

Cellares, in collaboration with Mitsui Fudosan, established Japan's first next-gen commercial production site for CAR-T cell therapies.

genengnews.com
Read News
Article 2
2025-04-03

Cellares Corporation receives award Advanced Manufacturing Technology.

Cellares announced that its Cell Shuttle has received the Advanced Manufacturing Technology designation from the FDA.

regmednet.com
Read News

Cellares FAQ - Frequently Asked Questions About Founder, CEO, Funding & Company Details

Find answers to the most common questions about Cellares including information about founders, CEO, funding history, investors, headquarters location, and company details. 15 frequently asked questions covering key information about the company.

Cellares Questions & Answers - Company Information

Q1

What is Cellares?

Cellares is the first Integrated Development and Manufacturing Organization (IDMO) dedicated to cell therapy manufacturing, utilizing advanced technologies to accelerate access to life-saving treatments.

Q2

Who founded Cellares?

Cellares was founded by Fabian Gerlinghaus.

Q3

How much funding has Cellares raised?

Cellares has raised a total of $$355 Million across 3 funding rounds. The most recent funding was completed on 2023-09-23.

Q4

Who are the investors in Cellares?

Cellares's key investors include Koch Disruptive Technologies.

Q5

Where is Cellares headquartered?

Cellares is headquartered in South San Francisco, United States.

Q6

When was Cellares founded?

Cellares was founded in 2019.

Q7

How many employees does Cellares have?

Cellares has 201-500 employees.

Q8

What was Cellares's latest funding round?

Cellares's latest funding round was a Series C round of $$255 Million completed on 2023-09-23.

Q9

What does the company do?

Cellares is focused on revolutionizing cell therapy manufacturing to make treatments more accessible and affordable for patients.

Q10

How much funding?

$355 Million

Q11

Latest funding date?

2023-09-23

Q12

Who are the investors?

Koch Disruptive Technologies

Q13

What are the challenges?

Scaling manufacturing processes Meeting global patient demand

Q14

What are the opportunities?

Expanding into new markets Partnerships with major pharmaceutical companies

Q15

Latest news?

Cellares, in collaboration with Mitsui Fudosan, established Japan's first next-gen commercial production site for CAR-T cell therapies. Cellares announced that its Cell Shuttle has received the Advanced Manufacturing Technology designation from the FDA.

More Information About Cellares

For additional details about Cellares, including the latest news, funding updates, and company developments, explore our comprehensive company database. Find information about startup funding, company valuations, executive leadership, and business intelligence data.